Natco Pharma Ltd. Share Price

Natco ₹1,279 Cr Rights Issue to Strengthen Balance Sheet

has approved a ₹1,279.36 crore rights issue, marking a significant capital-raising exercise for the pharmaceutical company. The issue will involve the issuance of 1.71 crore equity shares at ₹750 per share, with the proceeds providing additional financial flexibility for the company. The company will issue 1,70,58,082 new shares at ₹750 each, including a face value of ₹2 and a premium of ₹748 per share. If fully subscribed, the new shares would increase Natco Pharma's equity base by approximately 9.5%. The rights issue is structured as 2 new shares for every 21 shares held, with October 1, 2026 fixed as the record date. The issue is scheduled to open on October 12 and close on October 22, 2026. For existing shareholders, the rights structure allows them to maintain their proportional ownership by subscribing to their entitlement.

See More

Natco Pharma board approves rights issue to raise funds

Natco Pharma board approves rights issue to raise up to ₹1,279 crore SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826

Drug maker Natco Pharma on Friday said its board of directors has approved the issuance of equity shares through a rights issue to raise up to ₹1,279.35 crore. According to a regulatory filing, the company will issue up to 1,70,58,082 equity shares of face value of ₹2 each at an issue price of ₹750 per share to raise an amount not exceeding ₹1,279.35 crore. The rights issue has been approved at the entitlement ratio of 2 rights equity shares for every 21 fully paid-up equity shares held by eligible shareholders as on the record date, which has been fixed as October 1, 2026. The rights issue is scheduled to open on October 12, 2026, and close on October 22, 2026. The on-market renunciation period will run from October 12 to October 16, 2026. Upon full subscription, the company's outstanding equity shares will rise from 17,91,09,870 shares to 19,61,67,952 shares post-issue. The board also approved amendments to the company's code of conduct to regulate, monitor, and report trading by designated persons during its meeting held on Friday, the filing added. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More

Natco Pharma's Slide Continues Even as Its Sector Rallies

has been quietly bleeding for months, and today's close tells a mixed story. The stock settled at ₹818.25, actually up slightly from its previous close of ₹813.29, a modest gain of around 0.6%, but still well short of keeping pace with the broader Nifty Pharma index, which jumped 1.66% and snapped a five-session losing streak. So while Natco didn't fall today, it still lagged its own sector by a wide margin. The stock remains in a well-established downtrend. It's down roughly 10% over the past month and nearly 15% over six months, still trading much closer to its 52-week low of ₹789 than its high of ₹1,226.80. A rights issue and demerger are weighing on sentiment. On September 9, the board approved a ₹1,300 crore rights issue alongside an updated demerger plan, this kind of corporate action typically keeps investors on the sidelines until dilution and structure become clearer. Technicals had been signaling oversold conditions. As of mid-September, RSI was near 29 with a negative MACD, so today's modest bounce could be an early sign of that oversold pressure easing, though one day isn't enough to call a reversal. There's a longer-term growth angle too. The company invested $14 million in US biotech firm eGenesis in late August, showing it's still funding future pipeline bets even through the price weakness.

See More

NATCO PHARMA PROPOSES ₹1,300 CR RIGHTS ISSUE

NATCO PHARMA PROPOSES ₹1,300 CR RIGHTS ISSUE

NATCO Pharma has proposed a rights issue of equity shares with a face value of ₹2 each. The issue price is yet to be determined. The proposed rights issue will aggregate up to ₹1,300 crore, with the funds planned to be utilised for prepayment of borrowings, research and development initiatives, and inorganic growth opportunities. The fundraising is aimed at strengthening the company’s balance sheet while providing additional capital to support future expansion and strategic investments. The final issue price, number of shares and other key terms of the rights issue are yet to be announced. Impact: Positive — The proposed ₹1,300 crore fundraise could strengthen NATCO Pharma’s balance sheet through debt repayment while providing funds for R&D and inorganic growth. However, the impact on existing shareholders will also depend on the final issue price and extent of dilution.

See More

Natco Pharma’s Next Act: Beyond Generics

, traditionally known for its strong generics portfolio, is now diversifying into innovative therapies. CEO Rajeev Nannapaneni emphasized that while generics remain core, the company is actively investing in specialty drugs and new therapeutic areas to sustain long‑term growth. Focus on GLP‑1 Segment: The company is targeting semaglutide, a GLP‑1 receptor agonist used in diabetes and obesity treatment. With global demand surging, Natco aims to develop cost‑effective alternatives, positioning itself as a competitive player in this high‑growth segment. Pipeline Expansion: Natco is building a robust pipeline of niche products, including oncology and chronic disease therapies. The strategy is to identify areas with unmet medical needs and limited competition, thereby creating strong entry barriers and higher margins compared to traditional generics. Financial Discipline: Despite the push into new areas, Natco remains cautious about capital allocation. The company is balancing R&D investments with profitability, ensuring that expansion into specialty drugs does not compromise financial stability. Global Market Ambitions: Natco is eyeing international markets, particularly the U.S., for its upcoming launches. By leveraging partnerships and regulatory expertise, the company hopes to replicate its domestic success abroad, especially in segments where affordability is a key differentiator. Leadership Vision: Nannapaneni’s approach reflects a blend of pragmatism and ambition—retaining generics as a steady revenue base while gradually scaling up specialty and innovative products. This dual strategy is designed to future‑proof Natco against pricing pressures and intensifying competition in generics.

See More

Can GLP-1 drugs change India’s productivity story?

A drug can change more than a patient’s weight. It can change how often someone misses work. A recent Danish study of Ozempic users found that long-term sick leave fell after treatment, while employment itself did not meaningfully increase. The important lesson: better health does not automatically translate into more jobs or higher income—but it may help people stay healthier and more consistently at work. Now India is running a much bigger real-world experiment. Semaglutide’s key Indian patent expired in March 2026, opening the market to a wave of cheaper generic versions. Companies including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin, Alkem, Torrent Pharma and Natco Pharma have entered or developed products in this space. For investors, the interesting question isn't simply: “Who will sell the most GLP-1 drugs?” It is: Who can convert the GLP-1 opportunity into sustainable volumes, margins and market share? Sun Pharma

| Dr. Reddy’s Laboratories | Zydus Lifesciences | Lupin | Alkem Laboratories | Torrent Pharmaceuticals | Natco Pharma This is not a prediction that all will benefit equally. Competition, pricing pressure, regulatory approvals, manufacturing capacity and patient persistence could decide the winners. Healthcare breakthroughs create investment opportunities, but investors must separate market growth from individual company earnings and sustainable competitive advantage.

See More